Compare Diageo plc (DEO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Merck & Co., Inc. — how do they compare? Diageo plc trades at $86.73 (market cap $47.67B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 7.4× Diageo plc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Merck & Co., Inc. for 98 Days on average.
| DEO | MRK | |
|---|---|---|
Market Cap | $47.67B | $351.28B |
Volume | 893,372 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $156.43 |
52-Week Low | $72.47 | $82.49 |
Typical Hold Time | 66 Days | 98 Days |
Enterprise Value | $68.09B | $398.04B |
Dividend Yield | 2.3% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical signals from moving averages. The company shows strong profitability with 59.47% gross margins and has beaten earnings estimates in the last three quarters. Recent developments include a new CFO appointment and marketing initiatives across key brands. The stock faces headwinds from declining 2026 revenue projections but maintains solid cash flow generation.
DEO presents a mixed outlook with analyst consensus leaning bullish (49% buy ratings) but facing execution risks in its US turnaround. The stock's premium valuation (P/E 27.9) requires sustained earnings growth, while regulatory challenges in India and competitive pressures warrant monitoring. Near-term catalysts include dividend payments and brand revitalization efforts.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
